Retatrutide weight loss: what do clinical trials show?

What this page answers

The single most searched question about retatrutide is how much weight people actually lost in the studies. This page answers that narrowly: what the reported human trials measured for body weight, how the numbers changed with dose and duration, and what proportion of participants reached large reductions.

It deliberately does not repeat the full evidence overview. For how the trial programme is structured, what the metabolic and cardiovascular endpoints showed, and how strong the evidence base is overall, the retatrutide clinical trials guide covers that ground.

Retatrutide is investigational. Nothing below is a dosing schedule, a treatment recommendation, or a prediction of what any individual would experience.

Where the weight-loss numbers come from

Two tiers of human research produced the figures that circulate. The earlier tier is phase 2: a randomised, double-blind, placebo-controlled dose-ranging trial in adults with obesity that ran for 48 weeks, with a parallel 36-week trial in adults with type 2 diabetes where weight was a secondary endpoint.

The later tier is the phase 3 TRIUMPH programme — larger randomised trials, mostly running to 80 weeks, in defined populations. Several TRIUMPH results were communicated during 2026 as company-reported topline announcements rather than full peer-reviewed publications. That distinction matters: topline figures are the sponsor's summary of its own trial before independent review, and the detail that peer review normally surfaces is not yet public.

Every number below is a group mean from one of those trials unless stated otherwise. It is not a figure derived from user reports, supplier marketing, or extrapolation from other incretin drugs.

Weight loss reported in obesity without diabetes

TRIUMPH-1 studied adults with obesity over 80 weeks against placebo. The reported mean body-weight reductions were approximately 19.0% at 4 mg, 25.9% at 9 mg and 28.3% at 12 mg, compared with approximately 2.2% in the placebo group.

The threshold data is the part most people are actually looking for. In the reported 12 mg group, 45.3% of participants achieved a body-weight reduction of at least 30% — a proportion that had not previously been reported at that scale in this drug class.

The earlier 48-week phase 2 obesity trial pointed the same way at lower exposure, and its weight curves had not clearly flattened by the end of treatment. The longer phase 3 result is consistent with that trajectory continuing rather than contradicting it.

• 4 mg — approximately 19.0% mean body-weight reduction at 80 weeks
• 9 mg — approximately 25.9%
• 12 mg — approximately 28.3%
• Placebo — approximately 2.2%
• 12 mg group — 45.3% of participants reported reaching at least 30% weight loss

Weight loss reported in type 2 diabetes

TRIUMPH-2 studied adults with obesity or overweight and type 2 diabetes, also over 80 weeks. The reported mean weight reductions were 12.7% at 4 mg, 19.1% at 9 mg and 20.8% at 12 mg, against 4.0% with placebo.

Those figures are materially lower than the obesity-only trial at identical doses. That is not a quirk of one study — smaller weight reduction in type 2 diabetes populations is a consistent pattern across the whole incretin class, and it is the clearest illustration of why a headline percentage means little without the population attached to it.

Reported A1C reductions in the same trial ran to roughly 1.4–1.6% across the retatrutide groups versus about 0.2% on placebo, so the glycaemic and weight effects moved together rather than trading off.

Other populations studied

TRIUMPH-3 enrolled adults with severe obesity and established cardiovascular disease and reported mean weight reductions of 21.6% at 9 mg and 22.6% at 12 mg versus 3.2% with placebo over 80 weeks. Its cardiovascular-event analyses were inconclusive, with confidence intervals crossing 1; they are covered in the clinical trials guide rather than here.

TRIUMPH-4, in adults with obesity and knee osteoarthritis, reported up to approximately 28.7% mean weight loss at 68 weeks in the 12 mg group, alongside reported improvements in pain and function outcomes.

Read across the four trials, the pattern is stable: large mean reductions, clearly separated from placebo, with the size of the effect shifting according to the population enrolled rather than swinging unpredictably.

Is the effect dose-related?

Yes, and consistently so. In every reported trial where multiple dose arms were tested, mean weight reduction increased from the lower dose to the higher dose, and the phase 2 dose-ranging work was designed specifically to establish that relationship.

What a dose-response curve does not tell you is where the useful ceiling sits for an individual, or how tolerability changes across that range. Higher doses in these trials were reached through structured escalation schedules under monitoring, and gastrointestinal adverse events were more frequent at higher doses — which is the subject of the retatrutide side effects guide.

How this compares with semaglutide and tirzepatide

The honest answer is that no published head-to-head trial has randomised participants between retatrutide and either comparator. Any comparison is therefore across separate trials with different populations, durations, escalation schedules and endpoints — informative about the general scale of effect, but not a like-for-like result.

With that caveat, the reported mean weight reductions for retatrutide in obesity trials sit above the figures typically reported for semaglutide and tirzepatide in their own phase 3 programmes. The comparators, however, hold regulatory approvals, fully published trial reports and years of post-approval safety data, none of which retatrutide has.

For the evidence bases set side by side, see the retatrutide and tirzepatide comparison and the semaglutide and retatrutide comparison.

What these numbers mean in practice

A trial mean describes a group, not a person. Individual responses within incretin trials vary widely, and the participants behind these averages were screened against entry criteria, escalated on a defined schedule, monitored throughout and supported alongside the drug. That package is part of the result.

The trials also stop where the interesting question starts. None of the reported readouts characterises what happens to body weight after treatment ends, and weight regain after discontinuation has been documented across this drug class. Nothing in the retatrutide record contradicts or resolves that.

Finally, none of it transfers to unregulated material bought online. The figures describe a manufactured investigational product administered under supervision, and there is no evidence base at all for research-grade vials used without any of that.

Limitations and what is still uncertain

The weight-loss evidence for retatrutide is now among the strongest reported in the class on effect size, and among the thinnest on everything that takes time to establish.

• Much of the 2026 phase 3 weight data is company-reported topline, not peer-reviewed publication
• No published randomised head-to-head trial against semaglutide or tirzepatide
• Durability after treatment stops has not been characterised
• Longest reported exposure is around 80 weeks, which is short for a chronic condition
• Retatrutide is not approved anywhere; the record is investigational throughout

Bottom line

Reported human trials show large, dose-related, placebo-separated mean weight reductions — up to roughly 28% at 80 weeks in obesity without diabetes, and around 21% in obesity with type 2 diabetes — with a substantial minority of the highest-dose group reported to reach 30% or more.

Those results are real trial findings, not marketing claims. They are also recent, partly unpublished, produced under supervision, and silent on what happens afterwards.

Frequently asked questions

How much weight did people lose on retatrutide in clinical trials?

In the phase 3 TRIUMPH-1 trial in adults with obesity, reported mean body-weight reductions at 80 weeks were about 19.0% at 4 mg, 25.9% at 9 mg and 28.3% at 12 mg, versus about 2.2% with placebo. In adults with obesity or overweight and type 2 diabetes, TRIUMPH-2 reported 12.7%, 19.1% and 20.8% versus 4.0% with placebo. These are group means, and several figures are company-reported topline results rather than peer-reviewed publications.

How many people lost 30% or more of their body weight?

In the reported TRIUMPH-1 results, 45.3% of participants in the 12 mg group achieved a body-weight reduction of at least 30% over 80 weeks. That threshold figure applies to the highest dose arm in one trial in adults with obesity without diabetes, and should not be read across to other doses or populations.

Is retatrutide weight loss dose-dependent?

Yes. In every reported trial with multiple dose arms, mean weight reduction increased with dose, and the phase 2 programme was designed as dose-ranging to establish that relationship. Higher doses were reached through structured escalation under monitoring, and gastrointestinal adverse events were also more frequent at higher doses.

Does retatrutide cause more weight loss than semaglutide or tirzepatide?

No published randomised head-to-head trial has compared them, so any comparison is across separate trials with different populations and designs. The reported mean weight reductions for retatrutide in obesity trials are higher than the figures typically reported for semaglutide and tirzepatide, but the comparators have regulatory approval, fully published phase 3 data and years of post-approval safety experience that retatrutide does not.

Does the weight come back after stopping retatrutide?

The reported retatrutide trials did not characterise what happens after treatment ends, so there is no direct evidence either way. Weight regain following discontinuation has been documented across the incretin drug class more broadly, and nothing in the retatrutide record contradicts or resolves that.